Juvenile idiopathic arthritis and malignancy

Rheumatology (United Kingdom)

Volumn 53, Issue 6, 2014, Pages 968-974

  Ruperto, Nicolino ^a   Martini, Alberto ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Abatacept; Adverse events; Anti TNF therapy; Etanercept; Infliximab; Juvenile idiopathic arthritis; Lymphoma; Malignancy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ADVERSE DRUG REACTION; CANCER RISK; CARCINOMA; CHILDHOOD CANCER; CHRONIC INFLAMMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; FAMILY; GASTRIC MUCOSAL LYMPHOMA; HEALTH PRACTITIONER; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LARGE CELL LYMPHOMA; LEUKEMIA; MELANOMA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH LYMPHOMA; STUDY DESIGN; THYROID CARCINOMA; UTERINE CERVIX DYSPLASIA; YOLK SAC CARCINOMA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; PHARMACOVIGILANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH DESIGN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900813627     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket318     Document Type: Review

References (60)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 377:2138-49.
3. Regulation (EC) no. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) no. 1768/92, Directive 2001/20/EC, Directive 2001/ 83/EC and Regulation (EC) no. 726/2004. OJEUL 378:1-19. Available at http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2006:378: 0001:0019:EN:PDF (18 September 2013, date last accessed).
4. Ruperto N, Martini A. Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. BMJ 2000;320:1210-1.
5. Beukelman T, Patkar NM, Saag KG et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63: 465-82.
6. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
7. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo- controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
8. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
9. Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
10. Ruperto N, Quartier P, Wulffraat N et al. A phase II study to evaluate dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64: 557-67.
11. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
12. Ruperto N, Brunner HI, Quartier P et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406.
13. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled, withdrawal phase III trial. Lancet 2008;371: 998-1006.
14. De Benedetti F, Brunner HI, Ruperto N et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
15. Nielsen S, Ruperto N, Gerloni V et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26: 688-92.
16. Smolen JS, Nash P, Durez P et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
17. US Food and Drug Administration. FDA: Cancer Warnings Required for TNF Blockers. http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm175803.htm.4-8-2009 (3 September 2013, date last accessed).
18. Giannini EH, Ruperto N, Ravelli A et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
19. Ruperto N, Giannini EH, Pistorio A et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010; 62:3131-9.
20. Brunner HI, Lovell DJ, Finck BK et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64.
21. Giannini EH, Lovell DJ, Silverman ED et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. J Rheumatol 1996; 23:919-24.
22. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
23. Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
24. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 2009;68: 519-25.
25. Giannini EH, Ilowite NT, Lovell DJ et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
26. Otten MH, Prince FH, Twilt M et al. Tumor necrosis factorblocking agents for children with enthesitis-related arthritis- data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol 2011;38: 2258-63.
27. Prince FH, Geerdink LM, Borsboom GJ et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:138-42.
28. Horneff G, Foeldvari I, Minden K et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology 2011;50:230-6.
29. Bernatsky S, Rosenberg AM, Oen KG et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 2011;38:760-3.
30. Simard J, Neovius M, Hagelberg S et al. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62:3776-82.
31. Beukelman T, Haynes K, Curtis JR et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:1263-71.
32. Nordstrom BL, Mines D, Gu Y et al. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res 2012;64:1357-64.
33. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010;6:561-71.
34. US Food and Drug Administration. Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia). http://www.fda.gov/Drugs/Drug Safety/PostmarketDrugSafetyInformationforPatientsand Providers/DrugSafetyInformationforHeathcareProfessio nals/ucm070725.htm.6-4-2008 (3 September 2013, date last accessed).
35. Diak P, Siegel J, La GL et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24.
36. Lehman TJ. Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis? Arthritis Rheum 2010;62: 2183-4.
37. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986;29:801-7.
38. Ruperto N, Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheumatol 2011;7:6-7.
39. McCroskery P, Wallace CA, Lovell DJ et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18.
40. Cron RQ, Beukelman T. Guilt by association-what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23.
41. Onel KB, Onel K. Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web. Arthritis Rheum 2012;64:966-9.
42. Mannion ML, Beukelman T. What is the background incidence of malignancy in children with rheumatic disease? Curr Rheumatol Rep 2013;15:310.
43. Ruperto N, Lovell DJ, Quartier P et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792-802.
44. Ilowite N, Porras O, Reiff A et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37.
45. Carswell EA, Old LJ, Kassel RL. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
46. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
47. Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 2008;454:436-44.
48. Smitten AL, Simon TA, Hochberg MC et al. A metaanalysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
49. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
50. Setoguchi S, Solomon DH, Weinblatt ME et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2757-64.
51. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
52. Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 2009;60: 3180-9.
53. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904.
54. Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum 2012;64:21-32.
55. Commission implementing regulation (EU) no. 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities provided for in Regulation (EC) no. 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council. European Commission. http://www.emea.euro pa.eu/ema/index.jsp?curl=pages/regulation/general/gen eral_content_000492.jsp&mid=WC0b01ac058033e8ad, 1-21.2012 (3 September 2013, date last accessed).
56. Southwood TR, Foster HE, Davidson JE et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011;50:189-95.
57. Gerloni V, Pontikaki I, Gattinara M et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-- term prospective study of 163 patients. Ann Rheum Dis 2008;67:1145-52.
58. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritides: Durban, 1997. J Rheumatol 1998;25: 1991-4.
59. Petty RE, Southwood TR, Manners P et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
60. Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004;16:566-70.